All News

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.

Kelly Harris, APRN, an advanced practice registered nurse at Cincinnati Children's Hospital Medical Center, discusses using mobile care units to deliver dermatology care and education to underserved communities and how health systems can implement them.

At the Society for Pediatric Dermatology annual conference, Faye Brown, MSN, APRN, FNP-BC, a family nurse practitioner at the University of Colorado School of Medicine, highlights how telemedicine efforts can be utilized within dermatology triage systems to better care for pediatric patients.

James Treat, MD, goes over some of the ways food can impact patients' atopic dermatitis, as well as the pros and cons of elimination diets to mitigate food-related triggers.

Updates in nonsteroidal topical therapies were presented during a session at the Society for Pediatric Dermatology Annual Meeting.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

A presentation at the Society for Pediatric Dermatology Annual Conference discussed how to use generative artificial intelligence (AI) to improve processes while working in the dermatology space.

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.

Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.

Learn more about the 2025 Physician Fee Schedule, new health equity initiatives, improving maternal health, and pharmaceutical innovations at the Center on Health Equity & Access.

Jennifer Miller, MD, a pediatric endocrinologist at Lurie Children's Hospital, discusses the challenges of systemic corticosteroid use in children, such as adrenal suppression and growth delays.

Results from a national survey of patients with Duchenne muscular dystrophy (DMD) and their families found that patients and families want to be informed early about endocrine complications associated with glucocorticoid treatment.

No increased risks of preterm birth or perinatal outcomes were identified with maternal vaccination status, according to one study.

The Society for Pediatric Dermatology (SPD) Annual Meeting featured a new debates segment where experts in the field discussed preferred strategies for the treatment of pediatric skin conditions.

Doug Fulling, MA, discussed how introducing payers into clinical research earlier could help manufacturers, payers, and patients.

A Danish study found that living in cities with fewer than 50,000 residents and in newer, owned, and less dense homes is associated with a lower risk of developing chronic obstructive pulmonary disease (COPD).

Community support and molecular epidemiological approaches could help HIV prevention in Australia.

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo.

A multicenter pilot study concluded that dual therapy in spinal muscular atrophy (SMA) does not provide further benefits to infants at risk for SMA type 1.

Breast-conserving therapy for BRCA1/2 mutation carriers has higher risks of future breast cancers than the general population, but most patients avoid another cancer event, and many remain bilateral mastectomy–free after 20 years.

Pfizer announced plans for a once-a-day weight-loss pill; toxic metals have been found in over a dozen popular tampon brands across the US; CMS proposed a new rules impacting telehealth in the Medicare physician fee schedule (PFS) for 2025.

Patients with both diabetes and atherosclerotic cardiovascular disease (ASCVD) have about 1.5 times higher total direct health care expenditures than those without diabetes.

The 2025 Physician Fee Schedule includes a conversion factor reduction, expanded behavioral health services, extended telehealth waivers, new Quality Payment Program pathways, and measures to address suspect billing, alongside a Biden administration initiative introducing federal maternal health standards for hospitals.

The US Senate Committee on Health, Education, and Labor Pensions discussed actionable solutions to address the medical debt crisis impacting millions of individuals.

Today, the Siftwell 2024 Medicaid-Eligible Health Equity Index report highlighted ongoing challenges and barriers that underscore the need for systemic changes to improve health care access and outcomes for vulnerable groups.